Scarica l'app Stockscreener
77.09
16.71%
11.04
Pre-mercato:
76.50
-0.59
-0.77%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Cytokinetics stock hits 52-week high at 74.35 USD By Investing.com - Investing.com India
Cytokinetics (CYTK) Hits 52-Week High as Revenues Soar Over 1,000% - Yahoo Finance
5 Stocks Turning Heads With Double-Digit Gains - Insider Monkey
Cytokinetics Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Cytokinetics Q1 2026 results show revenue surge - Investing.com UK
Insider Sell Alert: Andrew Callos Sells Shares of Cytokinetics I - GuruFocus
Cytokinetics EVP Malik sells $270,795 in company stock By Investing.com - Investing.com Canada
Cytokinetics Shares Phase 3 ACACIA-HCM Win: Aficamten Hits Dual Endpoints in nHCM Trial - Yahoo Finance
Cytokinetics Q1 2026 Earnings Call Transcript - MarketBeat
Cytokinetics EVP Malik sells $270,795 in company stock - Investing.com
Cytokinetics (CYTK) Q1 2026 Earnings Transcript - AOL.com
Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance Singapore
Cytokinetics Insider Sold Shares Worth $270,795, According to a Recent SEC Filing - marketscreener.com
Cytokinetics announces proposed public offering of common stock - marketscreener.com
Cytokinetics (CYTK) EVP executes 3,500-share option exercise and sale - Stock Titan
Cytokinetics metrics satisfy in nHCM phase III - BioWorld News
Cytokinetics Incoffers common stock with aggregate public offering price of $650 millionSEC filing - marketscreener.com
Earnings call transcript: Cytokinetics Q1 2026 results show revenue surge By Investing.com - Investing.com Canada
Cytokinetics Q1 Loss Widens, Revenue Rises - marketscreener.com
Earnings Flash (CYTK) Cytokinetics Posts Q1 Loss $1.67, vs. FactSet Est of $1.65 Loss - marketscreener.com
Cytokinetics plans $650 million common stock offering - Investing.com
Cytokinetics plans $650M stock offering - MSN
Earnings Flash (CYTK) Cytokinetics, Incorporated Reports Q1 Revenue $19.4M, vs. FactSet Est of $8.5M - marketscreener.com
Cytokinetics (NASDAQ: CYTK) seeks $650M via common stock shelf offering - Stock Titan
Cytokinetics Highlights MYQORZO Progress and Cardiology Pipeline - TipRanks
[144] CYTOKINETICS INC SEC Filing - Stock Titan
Cytokinetics: Q1 Earnings Snapshot - marketscreener.com
Insider to sell 23,906 Common shares — Cytokinetics (NASDAQ: CYTK) - Stock Titan
Cytokinetics plans $650 million common stock offering By Investing.com - Investing.com Canada
Cytokinetics Announces Proposed Public Offering of Common Stock - The Manila Times
Director Wierenga trims Cytokinetics (CYTK) stake via option exercise and sale - Stock Titan
How This Biotech Scored 'A Clear Win' Where Bristol Myers Failed - Investor's Business Daily
Cytokinetics (CYTK) CFO trims stake with 23,906-share sale - Stock Titan
Biotech Cytokinetics seeks $650M stock sale, plus 15% option - Stock Titan
Cytokinetics stock adds more than $1 billion of valuation in a single day — Here's why - The Business Journals
BofA raises Cytokinetics price target on ACACIA trial results By Investing.com - Investing.com Australia
[Form 4] CYTOKINETICS INC Insider Trading Activity - Stock Titan
Cytokinetics (NASDAQ: CYTK) details MYQORZO rollout and $1.1B cash - Stock Titan
Cytokinetics (CYTK) EVP Callos exercises options and sells 11,333 shares - Stock Titan
[10-Q] CYTOKINETICS INC Quarterly Earnings Report - Stock Titan
MYQORZO launch drives revenue jump as Cytokinetics (NASDAQ: CYTK) posts Q1 2026 loss - Stock Titan
680 patients prescribed MYQORZO in Q1; EU approval follows - Stock Titan
BofA raises Cytokinetics price target on ACACIA trial results - Investing.com
Needham Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $102 - 富途牛牛
MSN Money - MSN
Cytokinetics earnings on deck as trial results loom large By Investing.com - Investing.com Australia
Cytokinetics earnings on deck as trial results loom large - Investing.com
CYTK Stock Jumps As Traders Brace For ACACIA Data - StocksToTrade
Why Cytokinetics Stock Is Surging After Trial Win - TipRanks
Cytokinetics gets jump on BMS as Myqorzo succeeds in non-obstructive HCM trial - FirstWord Pharma
Cytokinetics stock hits 52-week high after ACACIA-HCM trial - Yahoo Finance
Can Myqorzo drive growth for Cytokinetics amid competition? - MSN
Cytokinetics Announces Positive Topline Results from ACACIA-HCM - The National Law Review
Cytokinetics Stock Rallies After Pivotal Heart Disease Study Hits Dual Primary Endpoints - Benzinga
Cytokinetics stock hits 52-week high after heart drug passes expanded Phase 3 trial - qz.com
Are analysts too quick to gloss over Lilly’s liver case? - statnews.com
This Is Why Cytokinetics Stock (CYTK) Soared Today - TipRanks
CYTK Jumps As $95 Target, Trial Catalyst Ignite Trading - StocksToTrade
After rival fails, Cytokinetics could broaden Myqorzo label - pharmaphorum
Cytokinetics stock hits 52-week high at 74.35 USD - Investing.com
Cytokinetics heart drug scores in closely watched trial - BioPharma Dive
Cytokinetics surges 28% on promising heart drug results - Rolling Out
Cytokinetics' Myqorzo succeeds in landmark cardiomyopathy trial - Fierce Pharma
Cytokinetics announces positive topline results from Acacia-Hcm, the pivotal phase 3 clinical trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy - marketscreener.com
Cytokinetics’ aficamten meets trial goals in heart disease study By Investing.com - Investing.com Canada
Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy - The Manila Times
Cytokinetics heart disease drug meets main goals in late-stage study - TradingView
Cytokinetics stock surges on positive trial results By Investing.com - Investing.com Canada
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):